INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 136 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2021. The put-call ratio across all filers is 0.94 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,165,183 | +476.8% | 62,847 | +522.2% | 0.08% | +1166.7% |
| Q2 2021 | $202,000 | -13.3% | 10,100 | 0.0% | 0.01% | 0.0% |
| Q1 2021 | $233,000 | -31.9% | 10,100 | -27.0% | 0.01% | -33.3% |
| Q4 2020 | $342,000 | +8450.0% | 13,830 | +13730.0% | 0.01% | – |
| Q3 2020 | $4,000 | -71.4% | 100 | -66.7% | 0.00% | -100.0% |
| Q2 2020 | $14,000 | +40.0% | 300 | +98.7% | 0.00% | – |
| Q3 2019 | $10,000 | -16.7% | 151 | -1.9% | 0.00% | -100.0% |
| Q2 2019 | $12,000 | -84.0% | 154 | -77.2% | 0.00% | -75.0% |
| Q1 2019 | $75,000 | +971.4% | 674 | +823.3% | 0.00% | – |
| Q4 2018 | $7,000 | -22.2% | 73 | 0.0% | 0.00% | -100.0% |
| Q3 2018 | $9,000 | -99.2% | 73 | -99.4% | 0.00% | -98.6% |
| Q2 2018 | $1,103,000 | +981.4% | 13,143 | +649.3% | 0.07% | +677.8% |
| Q3 2017 | $102,000 | -95.2% | 1,754 | -90.0% | 0.01% | -95.5% |
| Q2 2017 | $2,127,000 | +1189.1% | 17,567 | +1103.2% | 0.20% | +1156.2% |
| Q1 2017 | $165,000 | +111.5% | 1,460 | +192.0% | 0.02% | +45.5% |
| Q4 2014 | $78,000 | – | 500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |